Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database

Obesity and diabetes mellitus (DM) have become significant burdens of global public health. It is estimated that more than half of the world's population will be diagnosed as overweight or obese by the year 2035 [1]; over 1.31 billion individuals will be affected by DM, and type 2 diabetes mellitus (T2DM) makes up the vast majority [2].

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can manage T2DM and obesity by stimulating glucose-dependent insulin, suppressing postprandial glucagon, inhibiting gastric emptying, reducing appetite and food intake, and protecting islet cell function [3]. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved GLP-1RAs for the therapy of T2DM in 2005 and 2006, and for obesity in 2014 and 2015, respectively. After that, liraglutide, dulaglutide, and semaglutide were approved for T2DM with major cardiovascular adverse events (MACEs). In March 2024, semaglutide was the first anti-obesity drug approved for overweight or obese adults with MACEs [4]. In addition to the approved indications mentioned above, a growing body of research supports the metabolic regulatory effects of GLP-1RAs, such as weight loss, improvement of insulin resistance, regulation of sex hormone levels, improvement of blood lipid profiles, and reduction of hepatic steatosis [5, 6]; therefore, GLP-1RAs are gradually showing beneficial effects in endocrine disorders or metabolic diseases such as polycystic ovary syndrome, lean nonalcoholic fatty liver disease, and obstructive sleep apnea [7], thus making GLP-1RAs one of the most popular and anticipated drug stars today.

Indeed, the increasing utilization of GLP-1RAs has provided us with a more profound comprehension of their adverse effects (AEs). In addition to commonly observed gastrointestinal AEs, particular attention was given to potential risks such as pancreatic cancer, thyroid cancer, cholelithiasis, hepatotoxicity, acute kidney injury, increased heart rate, angioedema, and injection site reactions [3, 8]. When it comes to neuropsychiatric AEs, some case reports mention that the clinical application of exenatide, semaglutide, and liraglutide may be related to the onset or recurrence of depression [9 –11]. In July 2023, the Icelandic Medicines Agency reported that patients treated with liraglutide and semaglutide were at possible risk of self-harm and suicide; thus, EMA soon announced a formal review of related risks with GLP-1RAs [12]. Concurrently, potential new safety concerns for GLP-1RAs, including alopecia, aspiration, and suicidal ideation, were identified within the FDA Adverse Event Reporting System (FAERS) database [13]. Also, the knowledge of neurological side effects for GLP-1RAs is limited, with only dizziness and taste disturbances mentioned in the drug instructions [14]. To the best of our knowledge, natural glucagon-like peptide-1 (GLP-1) is secreted by preproglucagon neurons in the central nervous system (CNS) [15]. Among patients with obesity and T2DM, the blood–brain barrier is dynamically altered or even impaired. Liraglutide, exenatide, and dulaglutide have been shown to rapidly cross the blood–brain barrier by passive diffusion, and tirzepatide crosses the blood–brain barrier slowly, presumably by extracellular pathways [16 –18]. Semaglutide cannot cross the normal blood–brain barrier directly but can bind to serum albumin and is taken up by Tanycyte cells through the ventricular walls of the CNS [19]. GLP-1RAs act directly or indirectly on GLP-1 receptors of the CNS to mediate reduced energy intake, increased satiety, facilitated insulin signaling, and other central effects. Given the emerging concerns about psychiatric effects and the gaps in our understanding of neurological impacts, it is crucial to investigate the neuropsychiatric side effects of GLP-1RAs more thoroughly.

In clinical practice, individuals with obesity and T2DM are at an increased risk of experiencing neuropsychiatric abnormalities and may require related medication [20 –25]. Therefore, it is crucial to consider the potential neuropsychiatric side effects when selecting appropriate antidiabetic medications. Furthermore, despite some clinical studies examining the psychiatric AEs of GLP-1RAs [26], their inclusion criteria and follow-up time limitations make it challenging for them to fully capture the neuropsychiatric effects of GLP-1RA drugs on obese and diabetic populations in real-world settings. FAERS is a comprehensive and openly accessible pharmacovigilance database containing real-world adverse drug reactions (ADRs) recorded by the FDA [27, 28], which serves as a valuable tool for assessing ADRs in the post-marketing phase.

In this study, we aim to update and broaden the understanding of psychiatric AEs linked to GLP-1RAs while also exploring their neurological AEs for the first time. We examine differences among various GLP-1RAs and indications. Furthermore, we compile reports on specific neuropsychiatric AEs associated with other antidiabetic and anti-obesity medications to provide improved clinical guidance for drug management.

As far as we know, this study is the first comprehensive pharmacovigilance investigation into the potential AEs of neuropsychiatric systems for GLP-1RAs through real-world data from the FAERS database. First, we detailed the clinical characteristics of reported cases of GLP-1RA-associated neuropsychiatric ADRs. Second, we grouped DM and weight-loss populations according to the main indications of GLP-1RAs and identified eight potential neuropsychiatric ADRs related to GLP-1RAs using disproportionate analysis. Then, we explored the specific effects of each drug of GLP-1RAs and other antidiabetic and anti-obesity medications on neuropsychiatric ADRs.

GLP-1RA-related neuropsychiatric AEs accounted for 13.5% among all the cases of GLP-1RAs in the FAERS database from 2010 to 2024Q1, and it showed an uptrend from 2015 to 2023, reflecting more and more concerns about GLP-1RA-related psychoneurological AEs. This was partly attributable to the fact that expanded indications, aggressive marketing by influencers, and high media exposure of GLP-1RAs in recent years contributed to more and more prescriptions [31]. Another explanation can be that the growing interest in their neuropsychiatric AEs in recent years encourage related declaration by clinicians and patients. Concerning suicidal risk with GLP-1RAs can also be link to prescription biases [32]. In addition, this may be due to the black swan event that the novel coronavirus pneumonia epidemic that began in late 2019 has exerted a significant impact on the physical and mental health of global population [33]. Consistent with previous studies [34, 35], semaglutide (22.4%) had a relatively higher proportion of neuropsychiatric AEs compared to other GLP-1RA medications, which may be attributed to its large market sales and the high level of concern about its safety in mental illness [31]. In addition, one study suggested that semaglutide was associated with drug abuse, prescription drug use without prescriptions, and intentional use [36], which also increased its proportion of neuropsychiatric AEs.

In terms of gender distribution, the proportion of females (63.2%) reporting ADR cases was significantly higher than that of males (31.5%), consistent with prior studies [34, 35, 37, 38]. This may be because a higher proportion of female patients who receive treatment of GLP-1RAs suffer neuropsychiatric abnormalities than males, especially in the obese population [39, 40], and prefer to share their discomfort symptoms. In the age group, except for missing data (45.9%), adults aged 18–65 made up the majority of reported ADRs (33.3%), and the proportion of patients under 18 years old and over 85 years old was less than 1%. Studies suggested that adult patients exhibited higher susceptibility to self-injurious and suicidal tendencies compared to other age groups [33]. In clinical practice, clinicians are more cautious about prescribing GLP-1RAs for pediatric and elderly patients. Furthermore, compared to adult patients, adolescents and the elderly lack related consciousness, tools, and skills to report ADRs.

Regarding the TTO of overall GLP-1RA neuropsychiatric ADRs, the median time was 16 days (IQR = 3–66 days). This suggested that close attention should be paid to neuropsychiatric feedback from initial medication. Among these GLP-1RAs, the TTO of dulaglutide was the shortest at 7 days, while exenatide was the longest at 28 days, parallel to previous pharmacovigilance studies [34]. We speculate that differences in TTO among GLP-1RAs drugs may be due to their various pharmacokinetics and the action mechanism with the nervous system. Moreover, we further found that the proportion of neuropsychiatric ADRs of GLP-1RAs overall decreased with the duration of application; this suggested that like gradual tolerance to gastrointestinal AEs, patients may also gradually develop tolerance to GLP-1RA-related neuropsychiatric AEs with the prolonged application of GLP-1RAs. Clinicians need to dynamically assess patients' neuropsychiatric side effects after clinical application of GLP-1RAs.

In the disproportionate analysis, statistically significant and potentially unexpected signal RORs were identified in olfactory nerve anomaly and sensory nerve disorder. Our research indicated that in the diabetic population, positive signals for olfactory nerve-related AEs were found in dulaglutide, liraglutide, and semaglutide, with semaglutide having the strongest signal; among antidiabetic medications, GLP-1RAs were also the only drug associated with olfactory AEs. In the obese population, only semaglutide had relevant signals, but the positive signals disappeared in the anti-obesity medicines. Of note, decreased olfactory acuity and olfactory dysfunction are found in the DM population. Some scholars believe that olfactory impairment can be an early risk marker for preclinical dementia in DM [41]. This may explain the positive signals of GLP-1RAs with olfactory abnormalities being stronger in DM than weight-loss populations. However, current research reckoned GLP-1RAs as improving olfactory impairment [41 –44]. They suggest that the olfactory bulb is a brain region responsible for the first processing of olfaction, and it produces GLP-1 and has the distribution of GLP-1 receptors, indicating the potential mechanism of GLP-1RAs for olfactory improvement [43, 44]. Our findings were contrary to the previous mainstream views. However, given that there was still a strong signaling association between GLP-1RAs and olfactory abnormalities among antidiabetic medications, it was reasonable to be wary of GLP-1RA-induced olfactory abnormalities. Considered differently, could what we believed to be the mechanism by which GLP-1RAs ameliorate olfactory dysfunction also exacerbate olfactory dysfunction in some cases, serving as a double-edged sword?

In the diabetic population, dulaglutide, liraglutide, semaglutide, and tirzepatide were all found to be associated with sensory abnormalities, of which semaglutide having the strongest signal; among antidiabetic medications, GLP-1RAs were the only ones with a moderately positive signal. However, current studies generally agree that GLP-1RAs can alleviate pain hypersensitivity and restore peripheral neuropathy [45, 46]. Besides, DM often causes sensory abnormalities due to combinations of neuropathy or vasculopathy. For these reasons, when a diabetic patient complains of a new onset sensory abnormality, we tend to attribute this to complications of DM. But in the group of antidiabetic medications, GLP-1RAs were significantly correlated with sensory abnormality compared to other drugs, which may suggest that we should be vigilant for the involvement of GLP-1RAs in the sensory abnormality of a patient with emerging sensory abnormality in whom GLP-1RAs were being applied, especially in patients who achieved adequate blood glucose control. In the weight-loss population, semaglutide was the only GLP-1RA drug with weak signals; among anti-obesity medications, GLP-1RAs still had signals but weaker than naltrexone-bupropion, phentermine, and phentermine-topiramate. Given that obesity itself caused sensory abnormalities [47], we believed that the association between GLP-1RAs and sensory abnormalities in obese populations needed to be evaluated more cautiously, and subsequent, larger-samples and well-designed studies are needed for further exploration.

Headache and migraine are common side effects of drugs, which can reduce drug adherence and lower patients' quality of life [48]. In the DM cohort, our study observed that all five GLP-1RAs were associated with headaches, dulaglutide, semaglutide, and liraglutide were linked to migraine, while this link was not seen in patients using these drugs for weight control. Also, among antidiabetic medications, only GLP-1RAs showed a positive signal for migraine and headaches, with liraglutide and semaglutide showing the strongest signals. Current research suggests a strong association between obesity and migraine [49, 50], while the relationship between DM and migraine remains controversial [51, 52]. Interestingly, despite higher doses of GLP-1RAs being used in weight loss populations and the apparent stronger connection between obesity and migraine, our findings indicate that headaches and migraines were more prominent in DM patients. DM patients are more likely to suffer from headaches due to hypoglycemia, diabetic ketoacidosis, cerebrovascular accidents, or other circumstances compared to the non-diabetic population. However, we only observed positive signals related to headaches in GLP-1RAs, rather than in other antidiabetic medications. Therefore, our finding suggested that headache may be associated explicitly with GLP-1RA treatment among the DM population. An article applied a network meta-analysis and found that GLP-1RA drugs significantly increased the risk of headache compared to insulin, thiazolidinediones, or placebo, with odds ratios of 1.34, 1.41, and 1.18, respectively [53]. According to the literature [53], GLP-1RAs cause headaches by increasing regional cerebral blood flow and decreasing blood pressure, resulting in the expansion of cerebral blood vessels and the stretch of peripheral nerves. In addition, GLP-1 receptors were widely distributed in the brain, suggesting that central action may also be one of the causes of headaches. It was worth noting that a case report suggested that GLP-1RA-induced nausea and vomiting might cause dehydration, leading to cerebral venous thrombosis and headache [54].

Depression, anxiety, suicide, or any other mental disorders are regarded as essential ADRs because they seriously affect the life quality of patients and even endanger life safety, and we observed weak signals among some GLP-1RAs. Regarding anxiety, we found that in patients with DM, semaglutide and exenatide were related to weak signals, and no similar signals were seen in weight-loss population. As for depression, only semaglutide had a weak positive signal in the DM population. Among other common antidiabetic medications, DPP-4 inhibitors were found with weak signals of anxiety and depression. Both DPP-4 inhibitors and GLP-1RAs belong to the category of incretin-based therapies, and although the action mechanisms of GLP-1RAs and DPP-4 inhibitors are different, their ultimate goal is the similar: to prolong the half-life of GLP-1 and increase its activity. This suggests that DPP-4 inhibitors may also influence psychoemotional responses through GLP-1RA-like effects. In terms of suicide, there was still a positive signal for semaglutide, and the signal seemed stronger for weight-loss than DM population. Potential associations between semaglutide and suicidal ideation have also been found in previous pharmacovigilance studies, and such associations were not observed in dulaglutide and exenatide [55, 56]. Among antidiabetic drugs, metformin showed a stronger suicide signal, which was in line with previous studies [55]. This indicated that more attention was paid to whether metformin increased the risk of suicide and that further studies were needed to investigate the relationships between metformin and suicide.

Semaglutide was associated with suicide more strongly in weight control than DM groups, which may be because obese people with larger doses of GLP-1RAs may lose more weight. Rapid weight loss can elicit significant emotional, biological, and psychological responses [32]. According to literature, GLP-1 can regulate neurotransmitter release (serotonin, dopamine, gamma-aminobutyric acid, and glutamate) to impact mood and psychology. GLP-1 receptors are found in emotion regulation areas such as the amygdala, dorsal raphe, and hippocampus. Additionally, GLP-1RAs can modulate CNS emotional responses by regulating taste and food-related reward [57 –59]. Some studies suggested that frequent gastrointestinal reactions related to GLP-1RAs may lead to mental and psychological problems in patients [34], and the most significant gastrointestinal risks were observed in patients receiving semaglutide treatment [60]. This may explain why semaglutide had positive signals in almost all these neuropsychiatric abnormalities.

While we have seen positive suicide signals for semaglutide, particularly in the weight loss population, some real-world studies found that there was no relationship between GLP-1RAs and mental disorders [26, 37, 38, 61 –64]; they even further pointed out that GLP-1RAs had a protective effect on depression and suicidal behaviors [61, 64, 65]. A pharmacovigilance study concluded that the combination of GLP-1RAs with other neuropsychiatric medications did not increase suicide risks [38]. On January 11, 2024, the FDA announced that no link was found between GLP-1RAs and the occurrence of suicidal thoughts or behaviors [66].

There are some limitations to this study. First, FAERS-based disproportionality analyses neither show causality nor quantify risks but only count the strength of the association. Then, in the FAERS database, it is not possible to know if patients had already comorbid psychiatric disorders and to assess all the co-prescriptions (that can also increase the risk of neuropsychiatric disorders). Finally, reporting bias, such as underreporting or overreporting due to varying levels of public awareness of medication side effects, especially in the context of the 78.6% of cases reported by non-healthcare professionals and our inability to differentiate between whether or not these reports were relevant to the litigation, could have introduced a potential for bias and affected our interpretation of the results. There are some strengths of this study. First, this study included a large number of cases of neuropsychiatric AEs related to GLP-1RAs, and second, the real data are a weakness in terms of data quality but also a strength as there are no "restrictions" on who receives the treatment, whereas randomized controlled trials have numerous exclusion criteria. Therefore, any conclusions drawn from pharmacovigilance analyses should be interpreted within the context of these constraints, and extensive prospective studies will need to be confirmed in the future.

In this study, we found, for the first time, positive signals for GLP-1RAs with migraine, olfactory abnormalities, and sensory abnormalities; we also observed positive suicide signals for semaglutide, especially in weight loss population. Among the common GLP-1RAs, semaglutide had a relatively higher proportion of neuropsychiatric AEs, and essentially had positive and the strongest signals across these wide range of neuropsychiatric abnormalities. GLP-1RA-related neuropsychiatric AEs mostly reported within 30 days. Clinicians should continue to balance the benefits and risks associated with GLP-1RAs with a patient-centered approach, which can be followed up by improving baseline screening for diabetes- and obesity-related neuropsychiatric abnormalities, enhancing regular follow-up and increasing clinical vigilance for unusual neuropsychiatric manifestations.